Identification of beta-arrestin-1 as a diagnostic biomarker in lung cancer

V. El-Khoury, M. Béland, A. Schritz, S.Y. Kim, P. V. Nazarov, L. Gaboury, K. Sertamo, F. Bernardin, R. Batutu, L. Antunes, C. W. Bennett, F. Faÿs, G. Berchem & Y. J. Kim

British Journal of Cancer. August 2018; https://doi.org/10.1038/s41416-018-0200-0 [Epub ahead of print]


Abstract

Background

Distinguishing lung adenocarcinoma (ADC) from squamous cell carcinoma (SCC) has a tremendous therapeutic implication. Sometimes, the commonly used immunohistochemistry (IHC) markers fail to discriminate between them, urging for the identification of new diagnostic biomarkers.

Methods

We performed IHC on tissue microarrays from two cohorts of lung cancer patients to analyse the expression of beta-arrestin-1, beta-arrestin-2 and clinically used diagnostic markers in ADC and SCC samples. Logistic regression models were applied for tumour subtype prediction. Parallel reaction monitoring (PRM)-based mass spectrometry was used to quantify beta-arrestin-1 in plasma from cancer patients and healthy donors.

Results

Beta-arrestin-1 expression was significantly higher in ADC versus SCC samples. Beta-arrestin-1 displayed high sensitivity, specificity and negative predictive value. Its usefulness in an IHC panel was also shown. Plasma beta-arrestin-1 levels were considerably higher in lung cancer patients than in healthy donors and were higher in patients who later experienced a progressive disease than in patients showing complete/partial response following EGFR inhibitor therapy.

Conclusions

Our data identify beta-arrestin-1 as a diagnostic marker to differentiate ADC from SCC and indicate its potential as a plasma biomarker for non-invasive diagnosis of lung cancer. Its utility to predict response to EGFR inhibitors is yet to be confirmed.

 

Publisher